Research
FORUM TRANSCRIPT

Stada – Q1 2022 Performance & European Generics Market Outlook – Part 1

  • Credit
  • Healthcare
  • Europe
PREMIUM

Specialist

Former senior executive at Stada Arzneimittel AG

Agenda

  • Stada’s underlying Q1 2022 performance, margin evolution and EBITDA adjustments
  • Russia-Ukraine conflict’s impact on Stada – portfolio review, regional performance outlook and impact on wider market
  • Stada generics – price, volume and LOE (loss of exclusivity) dynamics, key brand performance and Germany performance and tenders case study

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo